The improvements in survival seen in recent years with immunotherapy for advanced
cutaneous melanoma have not translated to mucosal melanoma (MM), where outcomes remain
poor. The quest to optimally harness the pro-immunogenic effects of RT in combination
with immune checkpoint inhibitors (ICI) continues, especially in cancers with suboptimal
response to ICI.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med. 2010; 363: 711-723
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.Lancet Oncol. 2015; 16: 908-918
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J Clin Oncol. 2014; 32: 1020-1030
- Efficacy and Safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis.J Clin Oncol. 2017; 35: 226-235
- Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med. 2015; 373: 23-34
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2015; 16: 375-384
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med. 2015; 372: 320-330
- Nivolumab plus ipilimumab in advanced melanoma.N Engl J Med. 2013; 369: 122-133
- Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.Oncology. 2011; 81 (34863): 353-358
- Postoperative radiotherapy for primary mucosal melanoma of the head and neck.Cancer. 2005; 103: 313-319
- Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients?.Ann Surg Oncol. 2010; 17: 40-44
- Vulvar melanoma at the M. D. Anderson cancer center: 25 years later.Int J Gynecol Cancer. 2001; 11: 359-364
- The national cancer data base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. the American college of surgeons commission on cancer and the American cancer society.Cancer. 1998; 83: 1664-1678
- Anorectal amelanotic melanoma.Colorectal Dis. 2008; 10: 612-615
- Changing epidemiology of anorectal melanoma.Dis Colon Rectum. 1999; 42: 1203-1208
- Importance of clear resection margins in anorectal malignant melanoma.Br J Surg. 2010; 97: 98-103https://doi.org/10.1002/bjs.6784
- Surgical treatment of anorectal melanoma: a systematic review and meta-analysis.BJS Open. 2021; 5 (PMID: 34958352): zrab107https://doi.org/10.1093/bjsopen/zrab107
- Postoperative radiotherapy in head and neck mucosal melanoma: a GETTEC study.Arch Otolaryngol Head Neck Surg. 2010; 136: 1219-1225
- Mucosal melanoma of the head and neck: a systematic review of the literature.Int J Radiat Oncol Biol Phys. 2014; 90: 1108-1118
- Mucosal melanoma of the head and neck: a population-based study from Slovenia, 1985-2013.Radiat Oncol. 2016; 11: 137
- Radical radiotherapy for 28 cases of mucosal melanoma in the nasal cavity and sinuses.Br J Radiol. 1991; 64: 1147-1150
- Radiotherapy after surgical resection for head and neck mucosal melanoma.Am J Clin Oncol. 2010; 33: 281-285
- A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan.Int J Radiat Oncol Biol Phys. 2004; 59: 495-500
- Radiation therapy for melanoma.in: Ward WH Farma JM Cutaneous Melanoma: Etiology and Therapy [Internet]. Codon Publications, Brisbane (AU)2017 (Chapter 8)
- Radiation therapy to convert the tumor into an in situ vaccine.Int J Radiat Oncol Biol Phys. 2012; 84: 879-880
- Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.Cancer Res. 2004; 64: 7985-7994
- Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.Cancer Immunol Immunother. 2009; 58: 517-530
- The synergistic effect of radiotherapy and immunotherapy: a promising but not simple partnership.Crit Rev Oncol/Hematol. 2017; 111: 124-132
- Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody.Clin Cancer Res. 2009; 15: 5379-5388
- Local tumor treatment in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma.Cancer Immunol Res. 2016; 4: 744-754
- Optimizing dose per fraction: a new chapter in the story of the abscopal effect?.Int J Radiat Oncol Biol Phys. 2017; 99: 677-679
- Immunologic correlates of the abscopal effect in a patient with melanoma.N Engl J Med. 2012; 366: 925-931
- The 'QUAD SHOT'–a phase II study of palliative radiotherapy for incurable head and neck cancer.Radiother Oncol. 2005; 77: 137-142
- Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomes.J Gynecol Oncol. 2016; 27: e59
- Initial experience with palliative “QUAD-SHOT” radiotherapy with concurrent and adjuvant PD-1 inhibitor for recurrent And/Or metastatic head and neck cancer.Int J Radiat Oncol Biol, Phys. 2020; 108 (Supplement p.e826)
- Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.J Pathol. 2013; 230: 261-269
- Effect of radiotherapy combined with pembrolizumab on local tumor control in mucosal melanoma patients.Front. Oncol. 2019; 9: 835
- Complete and durable response after radiation therapy to primary tumor site of a patient with metastatic anorectal mucosal melanoma with oligoprogression on nivolumab.Adv Radiat Oncol. 2020; 5: 503-510
- Combining hypofractionated radiation therapy with immunotherapy for anorectal malignant melanoma: a case report.Ther Radiol Oncol. 2019; 3: 1
- Radiotherapy-immunotherapy combination: how will we bridge the gap between pre-clinical promise and effective clinical delivery?.Cancers (Basel). 2021; 13: 457
- The abscopal effect of stereotactic radiotherapy and immunotherapy: fool's gold or El dorado?.Clin Oncol (R Coll Radiol). 2019; 31: 432-443
- The tumor microenvironment after radiotherapy: mechanisms of resistance and recurrence.Nat Rev Cancer. 2015; 15 (Erratum in: Nat Rev Cancer. 2015 Aug;15(8):509): 409-425https://doi.org/10.1038/nrc3958
- Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma.J Clin Oncol. 2021; 39: 30-37
- Stereotactic radiation therapy combined with immunotherapy against metastatic melanoma: long-term results of a phase 1 clinical trial.Int J Radiat Oncol Biol Phys. 2020; 108: 150-156
- A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.Transl Lung Cancer Res. 2021; 10: 2766-2778
- Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.J Immunother Cancer. 2019; 7: 237
- Pulsed radiation therapy to improve systemic control of metastatic cancer.Front Oncol. 2021; 11737425
- Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.J Immunother Cancer. 2020; 8e000537
- Targeting the tumor stroma to improve cancer therapy.Nat Rev Clin Oncol. 2018; 15: 366-381
- High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: results of a phase II trial.Radiother Oncol. 2021; 162: 60-67
- Combined nivolumab and ipilimumab in melanoma metastatic to the brain.N Engl J Med. 2018; 379: 722-730https://doi.org/10.1056/NEJMoa1805453
Article Info
Publication History
Published online: March 13, 2022
Accepted:
March 10,
2022
Received in revised form:
March 9,
2022
Received:
February 8,
2022
Footnotes
Submitted: Feb 8, 2022; Revised: Mar 9, 2022; Accepted: Mar 10, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
